Familial partial lipodystrophy associated with PPARG mutations (Q97029): Difference between revisions
From determinar.ia.br - Determine suas informações
Created a new Item |
Changed an Item |
||||||||||||||
| (6 intermediate revisions by the same user not shown) | |||||||||||||||
| description / pt-br | description / pt-br | ||||||||||||||
A lipodistrofia parcial familiar associada a mutações PPARG (receptor gama ativado proliferativo de peroxissoma) pertence ao grupo de síndromes de lipodistrofias caracterizadas por anomalias de distribuição do tecido adiposo e frequentemente associadas a resistência à insulina grave manifesta por hiperinsulinemia , intolerância a carboidratos ou diabetes, hipertrigliceridemia com baixos níveis de lipoproteínas de alta densidade (HDL) e hipertensão arterial. Acantose nigricante, esteatose hepática e síndrome dos ovários policísticos também são frequentes. | |||||||||||||||
| description / en | description / en | ||||||||||||||
Familial partial lipodystrophy associated with PPARG (peroxisome proliferative activated receptor gamma) mutations belongs to the group of lipodystrophy syndromes characterised by anomalies of adipose tissue distribution and often associated with severe insulin resistance manifested by hyperinsulinaemia (insulin levels above 20mUI/l), carbohydrate intolerance or diabetes, hypertriglyceridaemia with low levels of high-density lipoproteins (HDL) and arterial hypertension. Acanthosis nigricans, hepatic steatosis and polycystic ovary syndrome are also frequent. | |||||||||||||||
| Property / Canonical URI | |||||||||||||||
| Property / Canonical URI: https://id.who.int/icd/entity/2042807932 / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / CURIE | |||||||||||||||
CID11:ID_2042807932 | |||||||||||||||
| Property / CURIE: CID11:ID_2042807932 / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / Canary Token | |||||||||||||||
dki-india-ID_2042807932 | |||||||||||||||
| Property / Canary Token: dki-india-ID_2042807932 / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / Verification Status | |||||||||||||||
Concluído | |||||||||||||||
| Property / Verification Status: Concluído / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / Knowledge Architect | |||||||||||||||
| Property / Knowledge Architect: https://pauloleads.com.br/cases-publicos/ / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / Collection date | |||||||||||||||
15 August 2026
| |||||||||||||||
| Property / Collection date: 15 August 2026 / rank | |||||||||||||||
Normal rank | |||||||||||||||
Latest revision as of 13:03, 16 August 2026
Familial partial lipodystrophy associated with PPARG (peroxisome proliferative activated receptor gamma) mutations belongs to the group of lipodystrophy syndromes characterised by anomalies of adipose tissue distribution and often associated with severe insulin resistance manifested by hyperinsulinaemia (insulin levels above 20mUI/l), carbohydrate intolerance or diabetes, hypertriglyceridaemia with low levels of high-density lipoproteins (HDL) and arterial hypertension. Acanthosis nigricans, hepatic steatosis and polycystic ovary syndrome are also frequent.
| Language | Label | Description | Also known as |
|---|---|---|---|
| default for all languages | ID_2042807932 |
||
| English | Familial partial lipodystrophy associated with PPARG mutations |
Familial partial lipodystrophy associated with PPARG (peroxisome proliferative activated receptor gamma) mutations belongs to the group of lipodystrophy syndromes characterised by anomalies of adipose tissue distribution and often associated with severe insulin resistance manifested by hyperinsulinaemia (insulin levels above 20mUI/l), carbohydrate intolerance or diabetes, hypertriglyceridaemia with low levels of high-density lipoproteins (HDL) and arterial hypertension. Acanthosis nigricans, hepatic steatosis and polycystic ovary syndrome are also frequent. |
Statements
CID11:ID_2042807932
0 references
dki-india-ID_2042807932
0 references
Concluído
0 references
15 August 2026
0 references
